Novo Nordisk Pharma Ltd. and Health2Sync partner in Japan to expand digital diabetes management to healthcare providers and patients

As part of the partnership, Novo Nordisk Pharma Ltd. will support the distribution and adoption of Health2Sync's SyncHealth app and healthcare provider platform in Japan.
By Dean Koh
12:22 am

Credit: Health2Sync

Health2Sync and Novo Nordisk Pharma Ltd. are partnering in Japan to support digital diabetes management and facilitate communication between diabetics and healthcare providers. Last December, the two companies agreed to support the localisation and promotion of the “SyncHealth” App (known as Health2Sync outside of Japan) and web platform for patient management.

People living with diabetes require constant vigilance in making the right lifestyle choices and remembering to take their medications. Health2Sync bridges the lengthy gap between doctor visits by enabling frequent digital touch points between patients and healthcare providers. Through its behavioral AI engine, the App can provide hints and nudges concerning meals, exercise, and blood glucose management, delivered in a compelling and friendly way that encourages users to stay adherent to their treatment plans.

“When we met the team from Health2Sync, it was clear that we have a shared mission in improving outcomes for people with diabetes. With this partnership, combining the passion and commitment of both organizations, we believe we will demonstrate shared value for the patient, the physician, and the Japanese Healthcare provider,” said John Dawber, Vice President and Head of Marketing Division, Novo Nordisk Pharma Ltd.

“We are excited to be partnering with Novo Nordisk in Japan, where the market is receptive to innovation at improving treatment process and patient experiences,” said Ed Deng, Co-Founder and CEO of Health2Sync. 

As part of the partnership, Novo Nordisk Pharma Ltd. will support the distribution and adoption of the SyncHealth app and healthcare provider platform in Japan. In the future, Novo Nordisk Pharma Ltd. aims to wirelessly connect its insulin delivery devices, enabling auto data recording of self-injected insulin. The company announced the launch of two connected insulin pens in October 2018 and plans to roll out the two devices, dubbed the NovoPen 6 and NovoPen Echo Plus, worldwide, starting in early 2019.

The SyncHealth App and the SyncHealth Platform are products developed for people living with diabetes, and Health2Sync is solely responsible and liable for the products' usage. 

Also, when providing such products or services, Health2Sync directly acquires user data (including personal information) after obtaining user's consent, and Health2Sync is fully responsible and liable for preserving and processing such data. The SyncHealth App has been running for about five years and currently has more than 310,000 registered users. It is the number one diabetes App in Japan, Taiwan, Hong Kong and Malaysia in terms of downloads and App store (iOS and Android) ratings.

In December 2017, Health2Sync raised $6 million in Series B funding and the new funding was used to set up operations in Japan, deepen data-driven services, and build features specifically for health insurance partnerships. The Taipei, Taiwan-based company was first founded in 2013 and raised $3 million in funding from a combination of firms in Silicon Valley and Asia in August 2016.


The latest news in digital health delivered daily to your inbox.

Thank you for subscribing!
Error! Something went wrong!